Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

N-Methylphenethylamine

From Wikipedia, the free encyclopedia
Not to be confused withamphetamine orβ-Methylphenethylamine.

Pharmaceutical compound
N-Methylphenethylamine
Clinical data
Other namesNMPEA;N-Methyl-2-phenylethanamine;N-Methylphenethylamine;N-Methyl-β-phenethylamine
Identifiers
  • N-methyl-2-phenylethan-1-amine
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.008.758Edit this at Wikidata
Chemical and physical data
FormulaC9H13N
Molar mass135.210 g·mol−1
3D model (JSmol)
Density0.93 g/cm3
Boiling point203 °C (397 °F)
  • CNCCc1ccccc1
  • InChI=1S/C9H13N/c1-10-8-7-9-5-3-2-4-6-9/h2-6,10H,7-8H2,1H3 checkY
  • Key:SASNBVQSOZSTPD-UHFFFAOYSA-N checkY
  (verify)

N-Methylphenethylamine (NMPEA) is anaturally occurringtrace amine neuromodulator in humans that is derived from the trace amine,phenethylamine (PEA).[1][2] It has been detected in human urine (<1 μg over 24 hours)[3] and is produced byphenylethanolamine N-methyltransferase withphenethylamine as a substrate, which significantly increases PEA's effects.[1][2] PEA breaks down intophenylacetaldehyde which is further broken down intophenylacetic acid bymonoamine oxidase. When this is inhibited bymonoamine oxidase inhibitors, it allows more of the PEA to remain present and produce psychoactive effects.

PEA and NMPEA are bothalkaloids that are found in a number of different plant species as well.[4] SomeAcacia species, such asA. rigidula, contain remarkably high levels of NMPEA (~2300–5300 ppm).[5] NMPEA is also present at low concentrations (< 10 ppm) in a wide range of foodstuffs.[6]

NMPEA is apositional isomer ofamphetamine.[7]

Biosynthesis

[edit]
Biosynthetic pathways forcatecholamines andtrace amines in thehuman brain[8][9][10]
The image above contains clickable links
N-methylphenethylamine, anendogenous compound in humans,[2] is an isomer of amphetamine with the samebiomolecular target,TAAR1, aG protein-coupled receptor which modulates catecholamine neurotransmission.[11]

Chemistry

[edit]

In appearance, NMPEA is a colorless liquid. NMPEA is aweak base, with pKa = 10.14; pKb = 3.86 (calculated from data given as Kb[12]). It forms a hydrochloride salt, m.p. 162–164 °C.[13]

Although NMPEA is available commercially, it may be synthesized by various methods. An early synthesis reported by Carothers and co-workers involved conversion of phenethylamine to itsp-toluenesulfonamide, followed byN-methylation usingmethyl iodide, then hydrolysis of the sulfonamide.[12] A more recent method, similar in principle, and used for making NMPEA radio-labeled with14C in the N-methyl group, started with the conversion of phenethylamine to its trifluoroacetamide. This was N-methylated (in this particular case using14C – labeled methyl iodide), and then the amide hydrolyzed.[14]

NMPEA is a substrate for bothMAO-A (KM = 58.8 μM) andMAO-B (KM = 4.13 μM) from rat brain mitochondria.[15]

Pharmacology

[edit]

NMPEA is apressor, with 1/350 x the potency ofepinephrine.[16]

Like its parent compound, PEA, and isomer,amphetamine, NMPEA is a potentagonist ofhuman trace amine-associated receptor 1 (hTAAR1).[2][17] It has comparablepharmacodynamic andtoxicodynamic properties to that of phenethylamine, amphetamine, and othermethylphenethylamines in rats.[7]

As with PEA, NMPEA is metabolized relatively rapidly bymonoamine oxidases duringfirst pass metabolism;[2][17] both compounds are preferentially metabolized byMAO-B.[2][17]

Toxicology

[edit]

The "minimum lethal dose" (mouse, i.p.) of the HCl salt of NMPEA is 203 mg/kg;[18] the LD50 for oral administration to mice of the same salt is 685 mg/kg.[19]

Acute toxicity studies on NMPEA show an LD50 = 90 mg/kg, after intravenous administration to mice.[20]

References

[edit]
  1. ^abPendleton RG, Gessner G, Sawyer J (September 1980). "Studies on lung N-methyltransferases, a pharmacological approach".Naunyn-Schmiedeberg's Arch. Pharmacol.313 (3):263–8.doi:10.1007/bf00505743.PMID 7432557.S2CID 1015819.
  2. ^abcdefBroadley KJ (March 2010). "The vascular effects of trace amines and amphetamines".Pharmacol. Ther.125 (3):363–375.doi:10.1016/j.pharmthera.2009.11.005.PMID 19948186.Fig. 2. Synthetic and metabolic pathways for endogenous and exogenously administered trace amines and sympathomimetic amines ...
    Trace amines are metabolized in the mammalian body via monoamine oxidase (MAO; EC 1.4.3.4) (Berry, 2004) (Fig. 2) ... It deaminates primary and secondary amines that are free in the neuronal cytoplasm but not those bound in storage vesicles of the sympathetic neurone ...
    Thus, MAO inhibitors potentiate the peripheral effects of indirectly acting sympathomimetic amines ... this potentiation occurs irrespective of whether the amine is a substrate for MAO. An α-methyl group on the side chain, as in amphetamine and ephedrine, renders the amine immune to deamination so that they are not metabolized in the gut. Similarly, β-PEA would not be deaminated in the gut as it is a selective substrate for MAO-B which is not found in the gut ...
    Brain levels of endogenous trace amines are several hundred-fold below those for the classical neurotransmitters noradrenaline, dopamine and serotonin but their rates of synthesis are equivalent to those of noradrenaline and dopamine and they have a very rapid turnover rate (Berry, 2004). Endogenous extracellular tissue levels of trace amines measured in the brain are in the low nanomolar range. These low concentrations arise because of their very short half-life ...
  3. ^G. P. Reynolds and D. O. Gray (1978)J. Chrom. B: Biomedical Applications145 137–140.
  4. ^T. A. Smith (1977). "Phenethylamine and related compounds in plants."Phytochemistry16 9–18.
  5. ^B. A. Clement, C. M. Goff and T. D. A. Forbes (1998)Phytochemistry49 1377–1380.
  6. ^G. B. Neurath et al. (1977)Fd. Cosmet. Toxicol.15 275–282.
  7. ^abMosnaim AD, Callaghan OH, Hudzik T, Wolf ME (April 2013). "Rat brain-uptake index for phenylethylamine and various monomethylated derivatives".Neurochem. Res.38 (4):842–6.doi:10.1007/s11064-013-0988-1.PMID 23389662.S2CID 18514146.
  8. ^Broadley KJ (March 2010). "The vascular effects of trace amines and amphetamines".Pharmacology & Therapeutics.125 (3):363–375.doi:10.1016/j.pharmthera.2009.11.005.PMID 19948186.
  9. ^Lindemann L, Hoener MC (May 2005). "A renaissance in trace amines inspired by a novel GPCR family".Trends in Pharmacological Sciences.26 (5):274–281.doi:10.1016/j.tips.2005.03.007.PMID 15860375.
  10. ^Wang X, Li J, Dong G, Yue J (February 2014). "The endogenous substrates of brain CYP2D".European Journal of Pharmacology.724:211–218.doi:10.1016/j.ejphar.2013.12.025.PMID 24374199.
  11. ^Miller GM (January 2011)."The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity".J. Neurochem.116 (2):164–176.doi:10.1111/j.1471-4159.2010.07109.x.PMC 3005101.PMID 21073468.
  12. ^abW.H. Carothers, C. F. Bickford and G. J. Hurwitz (1927)J. Am. Chem. Soc.49 2908–2914.
  13. ^C. Z. Ding et al. (1993)J. Med. Chem.36 1711–1715.
  14. ^I. Osamu (1983)Eur. J. Nucl. Med.8 385–388.
  15. ^O. Suzuki, M. Oya and Y. Katsumata (1980)Biochem. Pharmacol.29 2663–2667.
  16. ^W. H. Hartung (1945)Ind. Eng. Chem.37 126–137.
  17. ^abcLindemann L, Hoener MC (May 2005). "A renaissance in trace amines inspired by a novel GPCR family".Trends Pharmacol. Sci.26 (5):274–281.doi:10.1016/j.tips.2005.03.007.PMID 15860375.In addition to the main metabolic pathway, TAs can also be converted by nonspecific N-methyltransferase (NMT) [22] and phenylethanolamine N-methyltransferase (PNMT) [23] to the corresponding secondary amines (e.g. synephrine [14], N-methylphenylethylamine and N-methyltyramine [15]), which display similar activities on TAAR1 (TA1) as their primary amine precursors.
  18. ^A. M. Hjort (1934)J. Pharm. Exp. Ther.52 101–112.
  19. ^C. M. Suter and A. W. Weston (1941)J. Am. Chem. Soc.63 602–605.
  20. ^A. M. Lands and J. I. Grant (1952). "The vasopressor action and toxicity of cyclohexylethylamine derivatives."J. Pharmacol. Exp. Ther.106 341–345.
Main articles
and
pharmaceuticals
Amphetamine
  • Adzenys ER
  • Adzenys XR-ODT
  • Dyanavel XR
  • Evekeo
  • Evekeo ODT
  • Mixed amphetamine salts
Levoamphetamine
N/A
Dextroamphetamine
  • Dexedrine
  • ProCentra
  • Zenzedi
Lisdexamfetamine
  • Vyvanse
Neuropharmacology
Biomolecular targets
Inhibitedtransporters
Active metabolites
Related articles
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Phenethylpyrrolidines
Racetams
Psychedelics
Tropanes
Tryptamines
Others
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
TAAR1Tooltip Trace amine-associated receptor 1
Agonists
Endogenous
Exogenous
Antagonists
Inverse agonists
TAAR5Tooltip Trace amine-associated receptor 5
Agonists
Inverse agonists
Notes: (1) TAAR1 activity of ligands varies significantly between species. Some agents that are TAAR1 ligands in some species are not in other species. This navbox includes all TAAR1 ligands regardless of species. (2) See the individual pages for references, as well as theList of trace amines,TAAR, andTAAR1 pages.
See also:Receptor/signaling modulators
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=N-Methylphenethylamine&oldid=1323026692"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp